Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, P.O. Box 80082, NL-3508 TB Utrecht, The Netherlands.
Faculty of Pharmacy, University of Ljubljana, 1000 Ljubljana, Slovenia.
Molecules. 2021 Feb 16;26(4):1037. doi: 10.3390/molecules26041037.
-GlcNAcylation is a posttranslational modification that occurs at serine and threonine residues of protein substrates by the addition of -linked β-d--acetylglucosamine (GlcNAc) moiety. Two enzymes are involved in this modification: -GlcNac transferase (OGT), which attaches the GlcNAc residue to the protein substrate, and -GlcNAcase (OGA), which removes it. This biological balance is important for many biological processes, such as protein expression, cell apoptosis, and regulation of enzyme activity. The extent of this modification has sparked interest in the medical community to explore OGA and OGT as therapeutic targets, particularly in degenerative diseases. While some OGA inhibitors are already in phase 1 clinical trials for the treatment of Alzheimer's disease, OGT inhibitors still have a long way to go. Due to complex expression and instability, the discovery of potent OGT inhibitors is challenging. Over the years, the field has grappled with this problem, and scientists have developed a number of techniques and assays. In this review, we aim to highlight assays and techniques for OGT inhibitor discovery, evaluate their strength for the field, and give us direction for future bioassay methods.
糖基化是一种翻译后修饰,通过在蛋白质底物的丝氨酸和苏氨酸残基上添加β-N-乙酰氨基葡萄糖(GlcNAc)部分来实现。有两种酶参与这种修饰:-GlcNac 转移酶(OGT),它将 GlcNAc 残基连接到蛋白质底物上,而-β-N-乙酰氨基葡萄糖苷酶(OGA),它将其去除。这种生物平衡对许多生物过程很重要,例如蛋白质表达、细胞凋亡和酶活性的调节。这种修饰的程度引起了医学界的兴趣,将 OGA 和 OGT 作为治疗靶点进行探索,特别是在退行性疾病中。虽然一些 OGA 抑制剂已经进入治疗阿尔茨海默病的 1 期临床试验,但 OGT 抑制剂仍有很长的路要走。由于表达复杂和不稳定,发现有效的 OGT 抑制剂具有挑战性。多年来,该领域一直在努力解决这个问题,科学家们已经开发了许多技术和测定方法。在这篇综述中,我们旨在强调用于 OGT 抑制剂发现的测定方法和技术,评估它们在该领域的优势,并为未来的生物测定方法提供方向。